Assessing Amicus Therapeutics (FOLD) Valuation After Recent Share Price Momentum And DCF Upside [Yahoo! Finance]
Amicus Therapeutics, Inc. (FOLD)
Last amicus therapeutics, inc. earnings: 11/11 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.amicusrx.com/investor-relations
Company Research
Source: Yahoo! Finance
Amicus Therapeutics (FOLD) has drawn attention recently as investors weigh its current share price of US$14.37 against the company's rare disease portfolio, revenue of US$634.21 million, and net loss of US$27.11 million. See our latest analysis for Amicus Therapeutics. At a share price of US$14.37, Amicus Therapeutics has seen a 32.08% 3 month share price return, while its 1 year total shareholder return of 61.46% contrasts with more modest multi year total shareholder returns. This suggests that momentum has picked up recently. If this kind of move in a rare disease name has your attention, it could be a good moment to widen your search with 33 healthcare AI stocks as potential next ideas on your radar. With shares near the US$14.50 analyst target, solid revenue of US$634.21 million, and a net loss of US$27.11 million, is Amicus Therapeutics still undervalued, or is the market already pricing in future growth? Most Popular Narrative: 90% Undervalued With Amicus Therapeut
Show less
Read more
Impact Snapshot
Event Time:
FOLD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FOLD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FOLD alerts
High impacting Amicus Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
FOLD
News
- Pombiliti (Amicus Therapeutics) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, Forecasts [Yahoo! Finance]Yahoo! Finance
- Genomenon and Amicus Therapeutics Partner to Advance Fabry Disease Awareness and Diagnosis [Yahoo! Finance]Yahoo! Finance
- Chris Duke joins RBL LLC leadership team as Operating Partner [Yahoo! Finance]Yahoo! Finance
- How The Amicus Therapeutics (FOLD) Story Is Shifting Inside BioMarin's Rare Disease Portfolio [Yahoo! Finance]Yahoo! Finance
- Amicus Therapeutics Buyout Advances As Valuation Gap Draws Investor Focus [Yahoo! Finance]Yahoo! Finance
FOLD
Earnings
- 2/20/26 - Beat
FOLD
Sec Filings
- 3/4/26 - Form 4
- 3/3/26 - Form 8-K
- 3/2/26 - Form 144
- FOLD's page on the SEC website